BACKGROUND: Mutations of the KRAS or BRAF genes are now recognized as prognostic markers for colorectal cancer (CRC). They are also important predictive markers for resistance to the monoclonal antibodies that target the epidermal growth factor receptor. METHODS: In this retrospective study, KRAS and BRAF mutations were analyzed using a direct sequence method in 254 Japanese CRC patients, and the associations between KRAS or BRAF mutations and clinicopathological characteristics or outcome were evaluated. RESULTS: KRAS and BRAF mutations were detected in 33.5 and 6.7 % of all patients, respectively. Consistent with previous reports, BRAF mutations were significantly correlated with the anatomical site of the tumor (P < 0.001), tumor grade (P = 0.001) and high frequency of microsatellite instability (P < 0.001). BRAF mutations were correlated with poor overall survival in the full patient cohort (P = 0.009). KRAS mutations were significantly correlated with poor recurrence-free survival (P = 0.03), particularly in patients with stage II CRC (P = 0.007). Cox regression analysis showed that KRAS mutations were a negative predictor of recurrence-free survival in patients with stage II CRC. CONCLUSION: KRAS mutation status could be a novel biomarker for predicting disease recurrence in Japanese patients with stage II CRC.
BACKGROUND: Mutations of the KRAS or BRAF genes are now recognized as prognostic markers for colorectal cancer (CRC). They are also important predictive markers for resistance to the monoclonal antibodies that target the epidermal growth factor receptor. METHODS: In this retrospective study, KRAS and BRAF mutations were analyzed using a direct sequence method in 254 Japanese CRC patients, and the associations between KRAS or BRAF mutations and clinicopathological characteristics or outcome were evaluated. RESULTS:KRAS and BRAF mutations were detected in 33.5 and 6.7 % of all patients, respectively. Consistent with previous reports, BRAF mutations were significantly correlated with the anatomical site of the tumor (P < 0.001), tumor grade (P = 0.001) and high frequency of microsatellite instability (P < 0.001). BRAF mutations were correlated with poor overall survival in the full patient cohort (P = 0.009). KRAS mutations were significantly correlated with poor recurrence-free survival (P = 0.03), particularly in patients with stage II CRC (P = 0.007). Cox regression analysis showed that KRAS mutations were a negative predictor of recurrence-free survival in patients with stage II CRC. CONCLUSION:KRAS mutation status could be a novel biomarker for predicting disease recurrence in Japanese patients with stage II CRC.
Authors: Monica M Bertagnolli; Mark Redston; Carolyn C Compton; Donna Niedzwiecki; Robert J Mayer; Richard M Goldberg; Thomas A Colacchio; Leonard B Saltz; Robert S Warren Journal: J Clin Oncol Date: 2011-07-11 Impact factor: 44.544
Authors: Brooke E Sylvester; Dezheng Huo; Andrey Khramtsov; Jing Zhang; Rana V Smalling; Sope Olugbile; Blase N Polite; Olufunmilayo I Olopade Journal: Clin Cancer Res Date: 2011-11-23 Impact factor: 12.531
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: Nicolas Moosmann; Ludwig Fischer von Weikersthal; Ursula Vehling-Kaiser; Martina Stauch; Holger G Hass; Herrmann Dietzfelbinger; Daniel Oruzio; Stefan Klein; Klaus Zellmann; Thomas Decker; Mathias Schulze; Wolfgang Abenhardt; Gerhard Puchtler; Herbert Kappauf; Johann Mittermüller; Christopher Haberl; Andreas Schalhorn; Andreas Jung; Sebastian Stintzing; Volker Heinemann Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff Journal: J Gastrointest Oncol Date: 2016-12
Authors: Lee Cheng Phua; Hui Wen Ng; Angie Hui Ling Yeo; Elya Chen; Michelle Shu Mei Lo; Peh Yean Cheah; Eric Chun Yong Chan; Poh Koon Koh; Han Kiat Ho Journal: Oncol Lett Date: 2015-08-03 Impact factor: 2.967
Authors: Hafeez Afolabi; Salzihan Md Salleh; Zaidi Zakaria; Ch'ng Ewe Seng; Siti Norasikin Binti Mohd Nafil; Ahmad Aizat Bin Abdul Aziz; Yusuf Wada; Ahmad Irekeola Journal: Biomed Res Int Date: 2022-06-23 Impact factor: 3.246
Authors: Leon Raskin; Jonathan C B Dakubo; Nicole Palaski; Joel K Greenson; Stephen B Gruber Journal: Cancer Epidemiol Date: 2013-08-17 Impact factor: 2.984
Authors: Neel Sengupta; Christopher Yau; Anuratha Sakthianandeswaren; Dmitri Mouradov; Peter Gibbs; Nirosha Suraweera; Jean-Baptiste Cazier; Guadalupe Polanco-Echeverry; Anil Ghosh; Mohamed Thaha; Shafi Ahmed; Roger Feakins; David Propper; Sina Dorudi; Oliver Sieber; Andrew Silver; Cecilia Lai Journal: Mol Cancer Date: 2013-01-03 Impact factor: 27.401